S&P 500   3,791.69
DOW   30,944.63
QQQ   314.64
S&P 500   3,791.69
DOW   30,944.63
QQQ   314.64
S&P 500   3,791.69
DOW   30,944.63
QQQ   314.64
S&P 500   3,791.69
DOW   30,944.63
QQQ   314.64
Log in
NASDAQ:LNTH

Lantheus Stock Forecast, Price & News

$15.55
+0.12 (+0.78 %)
(As of 01/19/2021 12:03 PM ET)
Add
Compare
Today's Range
$15.40
Now: $15.55
$15.67
50-Day Range
$13.16
MA: $14.31
$15.91
52-Week Range
$8.67
Now: $15.55
$19.23
Volume2,570 shs
Average Volume525,700 shs
Market Capitalization$1.04 billion
P/E Ratio194.40
Dividend YieldN/A
Beta1.32
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201 for use in MPI studies to detect cardiovascular disease; Gallium Ga 67 to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It serves radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic collaborations with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions; and POINT Biopharma, Inc. to treat metastatic castration resistant prostate cancer. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Lantheus logo

MarketRank

Overall MarketRank

1.88 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001
Employees508

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$347.34 million
Cash Flow$1.55 per share
Book Value$2.92 per share

Profitability

Net Income$31.67 million

Miscellaneous

Market Cap$1.04 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$15.55
+0.12 (+0.78 %)
(As of 01/19/2021 12:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lantheus (NASDAQ:LNTH) Frequently Asked Questions

How has Lantheus' stock price been impacted by Coronavirus (COVID-19)?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LNTH stock has increased by 14.1% and is now trading at $15.54.
View which stocks have been most impacted by COVID-19
.

Is Lantheus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Lantheus?

Wall Street analysts have given Lantheus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lantheus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Lantheus
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.10. The medical equipment provider earned $88.50 million during the quarter, compared to the consensus estimate of $88.86 million. Lantheus had a net margin of 0.12% and a return on equity of 11.05%. The company's revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $0.28 earnings per share.
View Lantheus' earnings history
.

What price target have analysts set for LNTH?

3 equities research analysts have issued 12-month target prices for Lantheus' stock. Their forecasts range from $14.00 to $29.00. On average, they anticipate Lantheus' stock price to reach $21.50 in the next year. This suggests a possible upside of 38.4% from the stock's current price.
View analysts' price targets for Lantheus
or view Wall Street analyst' top-rated stocks.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

Who are Lantheus' key executives?

Lantheus' management team includes the following people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 60, Pay $1.53M)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 53, Pay $804.4k)
  • Mr. John J. Bolla, Chief Operating Officer (Age 50, Pay $533.86k)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy and Gen. Counsel (Age 59, Pay $662.61k)
  • Mr. Mark Richard Kinarney, Sr. Director of Investor Relations
  • Ms. Meara Murphy, Director of Corp. Communications
  • Mr. Etienne Montagut, Sr. VP of Corp. Devel. (Age 45)
  • Ms. Linda S. Lennox, VP of Corp. Communications & Chief of Staff
  • Ms. Carol Walker, Sr. VP of Quality (Age 57)
  • Dr. Istvan Molnar M.D., Chief Medical Officer (Age 53)

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%) and Diversified Trust Co (0.02%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus
.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Lantheus company stock in the last year include John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, and Robert J Jr Marshall.
View insider buying and selling activity for Lantheus
or view top insider-selling stocks.

Which major investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Lantheus
or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $15.54.

How big of a company is Lantheus?

Lantheus has a market capitalization of $1.04 billion and generates $347.34 million in revenue each year. The medical equipment provider earns $31.67 million in net income (profit) each year or $1.17 on an earnings per share basis. Lantheus employs 508 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.